Aciex Enters Into Collaborative Research Agreement with Portola to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
Ora will provide clinical development and regulatory consulting services to the collaboration.
May Offer Faster, More Effective, Longer Lasting Relief
For over 10 years the FDA has been accepting electronic submissions of regulatory documents.
A sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye
First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
SAR 1118 is a first-in-class molecule that inhibits T-cell inflammation by blocking the binding of two key cellular surface proteins
Double-masked Phase 2 trial to evaluate the safety and efficacy of RGN-259 as a treatment of dry eye syndrome
Firms in addition ink manufacturing agreement for one of Aciex’s lead prescription candidates.
Euclid Systems partners with Ora, Inc. for development of its novel collagen-based drug delivery system for glaucoma treatment
Ora operates a clinical research facility and a large international investigator network.